Integra LifeSciences Expands Its Product Offering for Spinal Deformity
PLAINSBORO, N.J., March 20, 2013 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the addition of a second cobalt chrome rod for its Daytona™ and Malibu™ Spinal Systems. This new rod, the Enhanced Strength and Stiffness rod, or ESS+ rod, provides additional strength and stiffness over the existing cobalt chrome rod, and will enter controlled market release in the third quarter of 2013. Integra now offers multiple rod options in its various deformity systems, including titanium alloy, stainless steel and cobalt chrome, enhancing Integra's ability to offer surgeons versatile solutions for spinal deformity correction procedures.
"Deformity correction is a specialized segment of the spinal fixation market, where cases are often complex and outcomes may be life-changing," said Brian B. Nielsen, MD, Tucson Orthopaedic Institute. "The type of rod material is frequently dictated by the patient's condition. The ESS+ rod is a welcome addition to Integra's product line, and demonstrates their commitment to provide us with a broader selection of treatment options."
The Daytona Deformity System, powered by Malibu technology, is designed to address standard to complex deformity cases in adult patients. It combines unique implant designs, materials and innovative instrumentation to create a highly versatile system. The screws feature extended travel housings for 30mm of built in rod reduction, and the intuitive instrumentation accommodates multiple derotation techniques. The new ESS+ rod is available in straight and lordotic/kyphotic configurations.
"Integra's development efforts underscore our commitment to provide surgeons with comprehensive solutions for deformity correction procedures," said Kirt Stephenson, Integra's President, U.S. Spine. "We will continue to focus on the needs of surgeons and seek their input as we grow our presence in the spine market."
Integra's ESS+ rod will be available at Integra's booth (3465) at the 2013 AAOS Annual Meeting in Chicago, Illinois, March 20-22, 2013. Integra will also offer live demonstrations and opportunities for hands-on experience of its products.
Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive and general surgery. For more information, please visit www.integralife.com
The Integra LifeSciences Holdings Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=440
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of Integra products. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2012 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences Holdings Corporation
Gianna Sabella
Director, Corporate Communications
(609) 936-2389
gianna.sabella@integralife.com